Effects of the magnetic resonance contrast medium ferrioxamine methanesulfonate on systemic and renal hemodynamics in the anesthetized dog

William L. Niedrach, Frederick W. Tonetti, Richard W Katzberg, Thomas W. Morris, Janine A. Ventura, Saara Totterman, Louis R. Cos

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Ferrioxamine methanesulfonate (S-FDF) is a new magnetic resonance (MR) contrast agent developed to improve magnetic resonance imaging of the abdomen and pelvis. This stable complex of deferoxamine methanesulfonate and iron is excreted in the urine by glomerular filtration modified by active renal tubular resorption. This study examines the acute systemic and renal hemodynamic responses to this agent after intravenous administration either as an infusion of 25 mg/kg over 5 minutes or as a rapid bolus at a dose of 50 mg/kg. In eight anesthetized dogs, renal plasma flow (RPF) was measured with an electromagnetic flowmeter, and GFR was determined by the renal extraction of technetium-99m-DTPA. Mean arterial pressure (MAP), pulse rate, and a lead IIECG were assessed. At a dose of 25 mg/kg over 5 minutes, MAP decreased significantly (control 146.0 ± 6.5 mm Hg vs. 107 ± 18 mm Hg at 2 minutes;F,<.05). In two of the eight animals, the MAP dropped below 60 mm Hg. Significant decreases in GFR and RPF also were noted. All four of the animals receiving the rapid injection of S-FDF experienced profound hypotension (MAP < 50 mm Hg). The drop in heart rate from 152 ± 11.6 bpm to 121 ± 4.9 bpm was associated with a marked depression of the ST wave in the lead II ECG. Further animal studies are needed to assess the mechanism of toxicity and a potential synergism of action with pentobarbital anesthesia.

Original languageEnglish (US)
Pages (from-to)687-691
Number of pages5
JournalInvestigative Radiology
Volume23
Issue number9
StatePublished - 1988
Externally publishedYes

Fingerprint

Contrast Media
Arterial Pressure
Magnetic Resonance Spectroscopy
Hemodynamics
Dogs
Renal Plasma Flow
Kidney
Heart Rate
Technetium Tc 99m Pentetate
Flowmeters
Deferoxamine
Electromagnetic Phenomena
Technetium
Pentobarbital
Pelvis
Intravenous Administration
Abdomen
Hypotension
Action Potentials
Electrocardiography

Keywords

  • Contrast medium
  • Ferrioxamine methanesulfonate
  • Nuclear magnetic resonance

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Niedrach, W. L., Tonetti, F. W., Katzberg, R. W., Morris, T. W., Ventura, J. A., Totterman, S., & Cos, L. R. (1988). Effects of the magnetic resonance contrast medium ferrioxamine methanesulfonate on systemic and renal hemodynamics in the anesthetized dog. Investigative Radiology, 23(9), 687-691.

Effects of the magnetic resonance contrast medium ferrioxamine methanesulfonate on systemic and renal hemodynamics in the anesthetized dog. / Niedrach, William L.; Tonetti, Frederick W.; Katzberg, Richard W; Morris, Thomas W.; Ventura, Janine A.; Totterman, Saara; Cos, Louis R.

In: Investigative Radiology, Vol. 23, No. 9, 1988, p. 687-691.

Research output: Contribution to journalArticle

Niedrach, WL, Tonetti, FW, Katzberg, RW, Morris, TW, Ventura, JA, Totterman, S & Cos, LR 1988, 'Effects of the magnetic resonance contrast medium ferrioxamine methanesulfonate on systemic and renal hemodynamics in the anesthetized dog', Investigative Radiology, vol. 23, no. 9, pp. 687-691.
Niedrach, William L. ; Tonetti, Frederick W. ; Katzberg, Richard W ; Morris, Thomas W. ; Ventura, Janine A. ; Totterman, Saara ; Cos, Louis R. / Effects of the magnetic resonance contrast medium ferrioxamine methanesulfonate on systemic and renal hemodynamics in the anesthetized dog. In: Investigative Radiology. 1988 ; Vol. 23, No. 9. pp. 687-691.
@article{0a75c76fb8a54e6da9f5c879c602627d,
title = "Effects of the magnetic resonance contrast medium ferrioxamine methanesulfonate on systemic and renal hemodynamics in the anesthetized dog",
abstract = "Ferrioxamine methanesulfonate (S-FDF) is a new magnetic resonance (MR) contrast agent developed to improve magnetic resonance imaging of the abdomen and pelvis. This stable complex of deferoxamine methanesulfonate and iron is excreted in the urine by glomerular filtration modified by active renal tubular resorption. This study examines the acute systemic and renal hemodynamic responses to this agent after intravenous administration either as an infusion of 25 mg/kg over 5 minutes or as a rapid bolus at a dose of 50 mg/kg. In eight anesthetized dogs, renal plasma flow (RPF) was measured with an electromagnetic flowmeter, and GFR was determined by the renal extraction of technetium-99m-DTPA. Mean arterial pressure (MAP), pulse rate, and a lead IIECG were assessed. At a dose of 25 mg/kg over 5 minutes, MAP decreased significantly (control 146.0 ± 6.5 mm Hg vs. 107 ± 18 mm Hg at 2 minutes;F,<.05). In two of the eight animals, the MAP dropped below 60 mm Hg. Significant decreases in GFR and RPF also were noted. All four of the animals receiving the rapid injection of S-FDF experienced profound hypotension (MAP < 50 mm Hg). The drop in heart rate from 152 ± 11.6 bpm to 121 ± 4.9 bpm was associated with a marked depression of the ST wave in the lead II ECG. Further animal studies are needed to assess the mechanism of toxicity and a potential synergism of action with pentobarbital anesthesia.",
keywords = "Contrast medium, Ferrioxamine methanesulfonate, Nuclear magnetic resonance",
author = "Niedrach, {William L.} and Tonetti, {Frederick W.} and Katzberg, {Richard W} and Morris, {Thomas W.} and Ventura, {Janine A.} and Saara Totterman and Cos, {Louis R.}",
year = "1988",
language = "English (US)",
volume = "23",
pages = "687--691",
journal = "Investigative Radiology",
issn = "0020-9996",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Effects of the magnetic resonance contrast medium ferrioxamine methanesulfonate on systemic and renal hemodynamics in the anesthetized dog

AU - Niedrach, William L.

AU - Tonetti, Frederick W.

AU - Katzberg, Richard W

AU - Morris, Thomas W.

AU - Ventura, Janine A.

AU - Totterman, Saara

AU - Cos, Louis R.

PY - 1988

Y1 - 1988

N2 - Ferrioxamine methanesulfonate (S-FDF) is a new magnetic resonance (MR) contrast agent developed to improve magnetic resonance imaging of the abdomen and pelvis. This stable complex of deferoxamine methanesulfonate and iron is excreted in the urine by glomerular filtration modified by active renal tubular resorption. This study examines the acute systemic and renal hemodynamic responses to this agent after intravenous administration either as an infusion of 25 mg/kg over 5 minutes or as a rapid bolus at a dose of 50 mg/kg. In eight anesthetized dogs, renal plasma flow (RPF) was measured with an electromagnetic flowmeter, and GFR was determined by the renal extraction of technetium-99m-DTPA. Mean arterial pressure (MAP), pulse rate, and a lead IIECG were assessed. At a dose of 25 mg/kg over 5 minutes, MAP decreased significantly (control 146.0 ± 6.5 mm Hg vs. 107 ± 18 mm Hg at 2 minutes;F,<.05). In two of the eight animals, the MAP dropped below 60 mm Hg. Significant decreases in GFR and RPF also were noted. All four of the animals receiving the rapid injection of S-FDF experienced profound hypotension (MAP < 50 mm Hg). The drop in heart rate from 152 ± 11.6 bpm to 121 ± 4.9 bpm was associated with a marked depression of the ST wave in the lead II ECG. Further animal studies are needed to assess the mechanism of toxicity and a potential synergism of action with pentobarbital anesthesia.

AB - Ferrioxamine methanesulfonate (S-FDF) is a new magnetic resonance (MR) contrast agent developed to improve magnetic resonance imaging of the abdomen and pelvis. This stable complex of deferoxamine methanesulfonate and iron is excreted in the urine by glomerular filtration modified by active renal tubular resorption. This study examines the acute systemic and renal hemodynamic responses to this agent after intravenous administration either as an infusion of 25 mg/kg over 5 minutes or as a rapid bolus at a dose of 50 mg/kg. In eight anesthetized dogs, renal plasma flow (RPF) was measured with an electromagnetic flowmeter, and GFR was determined by the renal extraction of technetium-99m-DTPA. Mean arterial pressure (MAP), pulse rate, and a lead IIECG were assessed. At a dose of 25 mg/kg over 5 minutes, MAP decreased significantly (control 146.0 ± 6.5 mm Hg vs. 107 ± 18 mm Hg at 2 minutes;F,<.05). In two of the eight animals, the MAP dropped below 60 mm Hg. Significant decreases in GFR and RPF also were noted. All four of the animals receiving the rapid injection of S-FDF experienced profound hypotension (MAP < 50 mm Hg). The drop in heart rate from 152 ± 11.6 bpm to 121 ± 4.9 bpm was associated with a marked depression of the ST wave in the lead II ECG. Further animal studies are needed to assess the mechanism of toxicity and a potential synergism of action with pentobarbital anesthesia.

KW - Contrast medium

KW - Ferrioxamine methanesulfonate

KW - Nuclear magnetic resonance

UR - http://www.scopus.com/inward/record.url?scp=0023807426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023807426&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 687

EP - 691

JO - Investigative Radiology

JF - Investigative Radiology

SN - 0020-9996

IS - 9

ER -